BioCryst Pharmaceuticals announced it will discontinue internal discovery programs and close its Birmingham facility as it shifts focus to external innovation, while completing enrollment in a Phase 3 study for navenibart.
BioCryst Pharmaceuticals announced it will discontinue internal discovery programs and close its Birmingham facility as it shifts focus to external innovation, while completing enrollment in a Phase 3 study for navenibart.